Listing 1 - 10 of 16 | << page >> |
Sort by
|
Choose an application
nephrology --- arterial hypertension --- nephritis --- vasculitis --- renal transplant --- Nephrology --- Internal medicine --- Kidneys --- Nephrology.
Choose an application
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact
vascular remodeling --- Smooth Muscle Cell --- endothelial cell --- hypoxia --- Fibrosis --- pulmonary arterial hypertension --- Mitochondria --- Bleomycin --- Inflammation --- Iron
Choose an application
Nephrology --- Kidneys --- Diseases --- arterial hypertension --- dialysis and kidney transplants --- nephrology --- Nephrology. --- Diseases. --- Internal medicine --- Kidney diseases --- Nephritis --- Nephropathy --- Renal diseases --- Abdomen --- Urinary organs
Choose an application
arterial hypertension --- dialysis and kidney transplants --- nephrology --- Nephrology --- Kidneys --- Kidney Diseases. --- Nehprology --- Nephrology. --- Diseases --- Diseases. --- Internal medicine --- Kidney diseases --- Nephritis --- Nephropathy --- Renal diseases --- Disease, Kidney --- Diseases, Kidney --- Kidney Disease --- Renal Replacement Therapy --- Abdomen --- Urinary organs --- Periodical.
Choose an application
arterial hypertension --- surgical treatment --- regulatory-adaptive status --- children cardio-respiratory --- synchronism treatment --- diabetes --- Medicine --- Medicine. --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Health Workforce
Choose an application
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological regulation of blood pressure, and of heart and kidney functions. NPs have also been implicated in the pathogenesis of several cardiovascular diseases (CVDs), including hypertension, atherosclerosis, heart failure, and stroke. A fine comprehension of the molecular mechanisms dependent from NPs and underlying the promotion of cardiovascular damage has contributed to improve our understanding of the molecular basis of all major CVDs. Finally, the opportunity to target NPs in order to develop new therapeutic tools for a better treatment of CVDs has been developed over the years. The current Special Issue of the Journal covers all major aspects of the molecular implications of NPs in physiology and pathology of the cardiovascular system, including NP-based therapeutic approaches.
postmortem biochemistry --- medulla --- animal models --- remodeling --- BNP --- PCSK9 --- guanylyl cyclase/natriuretic peptide receptor-A --- cardiorenal syndrome --- forensic medicine --- preserved ejection fraction --- kidney --- renin-angiotensin-aldosterone system --- atrial fibrillation --- vasopressor --- congestive heart failure --- atrial natriuretic peptide --- gene-knockout --- obesity --- heart failure --- angiogenesis --- adipose tissue --- vascular --- LDL receptor --- metabolic syndrome --- linkage analysis --- cardiometabolic disease --- cardiomyocyte --- cardiac dysfunction --- cardiac hypertrophy --- insulin --- lipid metabolism --- cGMP --- Idiopathic Pulmonary Arterial Hypertension (IPAH) --- Natriuretic Peptide Clearance Receptor (NPR-C) signaling --- gene-duplication --- renin–angiotensin system --- natriuretic peptides --- angiotensin receptor–neprilysin inhibitor --- cardiac remodelling --- ARNi --- NT-proBNP --- inflammation --- pulmonary arterial hypertension --- vascular homeostasis --- endothelial cell --- Atrial Natriuretic peptide --- natriuretic peptide --- vasodilator --- stroke --- genetic variants --- arterial hypertension --- fibroblast --- MANP --- hypertension --- guanylyl cyclase receptor A
Choose an application
Pulmonary arterial hypertension is a severe and progressive disorder affecting the blood vessels in the lungs. Typically, symptoms first appear at around 30–40 years of age and, without treatment, can lead to fatal heart disease within a few years. Genetic studies over the past decade have identified numerous genes that contribute to disease progression but, for many sufferers, the underlying genetic cause remains elusive. The collection of reviews and original research articles contained within this book provide an overview of recent advancements in understanding the genetic risk factors for pulmonary arterial hypertension. We further examine the emerging interplay between genetic variants and clinical outcomes, providing a framework for new treatments and improved patient care.
pulmonary arterial hypertension --- massive parallel sequencing --- NGS --- digenic inheritance --- and genetics --- BMPR2 promoter --- pathogenic variant --- heritable pulmonary arterial hypertension --- genetic analysis --- NGS gene panel --- BMPR2 --- TBX4 --- GDF2 --- EIF2AK4 --- genomics --- pediatrics --- lung disease --- endothelial cells --- smooth muscle cells --- DNA damage --- DNA repair --- expression quantitative trait locus --- eQTL --- blood --- genetics --- exome sequencing --- molecular genetics --- paediatrics --- bone morphogenetic protein receptor type 2 --- heritable --- familial --- estrogen --- estradiol --- penetrance --- gender --- PAH --- forward phenotyping --- forward genetics --- reverse genetics --- reverse phenotyping --- intermediate phenotypes --- whole-genome sequencing --- epigenetic inheritance --- genetic heterogeneity --- phenotypic heterogeneity --- pulmonary hypertension --- bone morphogenetic protein receptor 2 --- signaling --- repurposed drugs --- pharmaceuticals --- miRNA --- clinical trials --- n/a
Choose an application
Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs.
quantum dots (QDs) --- DNAzyme --- ROS --- Amplex Red --- light-induced activity --- DNA methylation --- histone code --- microRNA --- nanoparticles --- noncoding RNA --- pulmonary arterial hypertension --- aptamer --- aptasensor --- influenza --- SERS --- virus detection --- α-synuclein --- antisense oligonucleotide --- dopamine neurotransmission --- double mutant A30P*A53T* --- motor deficits --- Parkinson’s disease --- transgenic mouse model --- G-quadruplexes --- covalent dimer construct --- anti-proliferative activity --- primary cell culture of human glioma --- antisensense oligonucleotide --- Foxp3 --- regulatory T cells --- vaccine immunogenicity --- Sporothrix schenckii --- Marfan syndrome --- fibrillin-1 --- antisense oligonucleotides --- exon skipping --- splice-switching
Choose an application
This e-book summarises the latest advances in the rheumatic diseases with a focus on the recent efforts of vascular and pulmonary manifestations and anticipate the new and future directions of these research topic. Rheumatic diseases represent a heterogeneous group of severe autoimmune disorders. The present Special Issue aims to provide an overview of the complexity of vascular and pulmonary manifestations of rheumatologic diseases and helps in knowledge to manage them. The eleven published articles here collected underline the complexity of rheumatic diseases and the difficult to treated them. The manuscripts provide an overview of the pathophysiology and current treatment regimes of these disorders, highlighting tools which assist with diagnosis, risk stratification and therapy. Finally, we underline the importance of a multidisciplinary team working using the skills of clinicians, radiologists, and pathologists.
systemic sclerosis --- scleroderma --- interstitial lung disease --- pulmonary function tests --- high-resolution computed tomography --- rheumatic --- pulmonary arterial hypertension --- targeted therapy --- systemic lupus erythematosus --- airway disease --- shrinking lung syndrome --- diffuse alveolar hemorrhage --- pleurisy --- infection --- cardiopulmonary exercise testing --- osteopontin --- connective tissue diseases --- pulmonary involvement --- microvascular involvement --- nailfold capillaroscopy --- rheumatoid arthritis --- interstitial lung diseases --- CX3CL1/fractalkine --- CX3CR1 --- M1 macrophage --- M2 macrophage --- SKG mice --- heart failure --- 3D-echocardiography --- ventricular function --- outcome --- ventricular-arterial coupling --- antifibrotic agents --- COVID-19 --- IPF --- progressive fibrosing ILD --- UIP --- pharmacological interactions --- fibromyalgia --- gastrointestinal symptoms --- probiotic --- VSL#3® --- efficacy --- tolerability --- polymyalgia rheumatica --- vagus nerve stimulation --- inflammatory response --- PMR --- t-vns
Choose an application
This book focuses of the neurotransmission phenomenon. By definition, neurotransmitters are chemicals that enable communication, i.e., the flow of nerve impulses between nerve cells or between nerve cells and muscles and glands. Recently, one can distinguish excitatory and inhibitory mediators, both of which are endo–exogenous compounds that control the function of the whole organism. From a chemical point of view, neurotransmitters belong to many different structural groups, such as amino acids (such as glycine), peptides (such as substance P, somatostatin), monoamines (such as noradrenaline or dopamine), purine derivatives (such as adenosine), gases (such as nitrogen, NO, carbon monoxide CO), and acetylcholine. From a medical point of view, disturbances in the concentration of neurotransmitters in the body result in the occurrence of mental disorders and diseases (such as depression, schizophrenia, Parkinson’s disease) and contribute to the occurrence of dementia (including Alzheimer’s disease), among other diseases. However, the problem is much wider. These disorders can lead to a number of cardiovascular diseases and can lead to the development of vascular diseases of the brain as well as in many other organs. Therefore, pharmacological intervention is a therapy that tries to interfere with regulatory processes year after year. Such treatments improve survival, reduce the frequency of readmission, and improve patients' quality of life.
white matter hyperintensities --- dysautonomia --- genetic polymorphisms --- dementia --- levodopa --- renin-angiotensin system --- orthostatic hypotension --- reserpine-induced fibromyalgia model --- vortioxetine --- ropinirole --- serotonin and dopamine in fibromyalgia --- mouse --- dopamine --- acetylcholine --- glutamate --- BDNF --- serotonin --- neurotransmitters --- statins --- neurodegenerative diseases --- stroke --- depression --- androgenetic alopecia --- 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors --- mixed dyslipidemia --- risk factors --- halogenated pyrazolines --- monoamine oxidase inhibitors --- kinetics --- reversibility --- molecular dynamics --- guanylate cyclase (GC) --- chronic heart failure (CHF) --- pulmonary arterial hypertension (PAH) --- tiagabine --- cardiac voltage-gated ion channels --- molecular modeling --- ECG study --- SGLT2i --- sodium-glucose cotransporter 2 inhibitors --- neuroprotection --- atheroprotection --- mTOR --- type 2 diabetes mellitus --- cognitive impairment --- inflammation --- oxidative stress --- antibiotics --- neurotoxicity --- adverse drug reaction --- neurotransmission --- 5-HT receptors --- gastrointestinal tract
Listing 1 - 10 of 16 | << page >> |
Sort by
|